DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation, commonly referred to as DMK, is a prominent player in the pharmaceutical industry, headquartered in the United States. Founded in 1990, the company has established itself as a leader in the development and manufacturing of innovative pharmaceutical products, particularly in the areas of dermatology and wound care. With a strong operational presence across North America and Europe, DMK Pharmaceuticals is renowned for its commitment to quality and efficacy. The company’s core offerings include advanced topical formulations and therapeutic solutions that address a variety of skin conditions, setting them apart through their unique blend of science and nature. Recognised for its dedication to research and development, DMK has achieved significant milestones, including numerous patents and awards that underscore its market position. As a trusted name in the pharmaceutical sector, DMK Pharmaceuticals continues to enhance patient care through its cutting-edge products and solutions.
DitchCarbon Score
How does DMK Pharmaceuticals Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DMK Pharmaceuticals Corporation's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
DMK Pharmaceuticals Corporation's reported carbon emissions
DMK Pharmaceuticals Corporation, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As a result, DMK Pharmaceuticals Corporation's climate commitments remain unclear, and there are no inherited emissions data from a parent or related organization. The lack of emissions reporting and reduction initiatives suggests that the company may need to enhance its focus on sustainability and climate action to align with industry best practices.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DMK Pharmaceuticals Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
